| Therapeutic | Bexatamig |
| Target 1 | IL3RA/CD123 |
| Heavy Chain 1 | EVQLVQSGAEVKKPGESLKISCKGSGYSFTDYYMKWARQMPGKGLEWMGDIIPSSGATFYNQKFKGQVTISADKSISTTYLQWSSLKASDTAMYYCARSHLLRASWFAYWGQGTMVTVSS |
| Light Chain 1 | DIVMTQSPDSLAVSLGERATINCESSQSLLSSGNQKNYLTWYQQKPGQPPKPLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGQGTKLEIK |
| 100% seqID Fv 1 Structure | 4jzj [Fvs: AB, HL] |
| 99% seqID Fv 1 Structure | None |
| 95-98% seqID Fv 1 Structure | None |
| Target 2 | NCR1/NKP46/NKp46/LY94/CD335 |
| Heavy Chain 2 | QVQLVQSGAEVKKPGSSVKVSCKASGYTFSDYVINWVRQAPGQGLEWMGEIYPGSGTNYYNEKFKAKATITADKSTSTAYMELSSLRSEDTAVYYCARRGRYGLYAMDYWGQGTTVTVSS |
| Light Chain 2 | DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQQGNTRPWTFGGGTKVEIK |
| 100% seqID Fv 2 Structure | 6iap [Fvs: HL], 6ias [Fvs: HL] |
| 99% seqID Fv 2 Structure | None |
| 95-98% seqID Fv 2 Structure | None |
| 100% seqID Structure [Fv 1] | 4jzj [Fvs: AB, HL] |
| 100% seqID Structure [Fv 2] | 6ias [Fvs: HL] |
| 100% seqID Structure [Fv 2] | 6iap [Fvs: HL] |
Follow these links to our prediction tools:
| Format | Bispecific (H-gamma1-VH-G1CH1h_L-kappa)_L-kappa-G1hCH2CH3 |
| Isotype | G1;G1 |
| Highest Clinical Trial (Feb '25) | Phase-I/II |
| Estimated Status (Feb '25) | Active |
| Recorded Developmental Technology | |
| INN Year Proposed | 2024 |
| INN Year Recommended | 2024 |
| Companies Involved | Innate Pharma |
| Conditions Approved | na |
| Conditions Active | Acute myeloid leukaemia, Myelodysplastic syndromes, Precursor B-cell lymphoblastic leukaemia-lymphoma |
| Conditions Discontinued | na |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
